Peter Mac Partners with Algorae on AI Validation
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Algorae Pharmaceuticals Limited has announced a partnership with the Peter MacCallum Cancer Centre for a second AI-driven drug synergy screening program. This project is expected to generate key preclinical data within six months, which will aid in the development of Algorae's pipeline. The partnership is seen as a significant step in validating Algorae's AI-driven approach to drug discovery and could lead to further clinical studies or partnerships.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Algorae Pharmaceuticals Limited on 6ix
Earlier from Algorae Pharmaceuticals
- Half Year Report and Appendix 4D
- Algorae Signs License and Supply Agreement with Cadila
- Quarterly Activities Report /Appendix 4C Cash Flow Statement
- $3 million Debt Facility Secured with ScotPac
- AlgoraeOS v2 Identifies 90 Drug Combination Candidates
Later from Algorae Pharmaceuticals
- TGA Accepts Initial Registration Dossier for Evaluation
- Algorae Pharmaceuticals Ltd Raises $3.9m
- Algorae and Zydus Enter Exclusive Commercial Agreement
- 1AI Executes License & Supply Agreement with Torrent Pharma
- Algorae Expands AI Drug Combination Pipeline
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals